Alkermes announces the appointment of Cato T. Laurencin, M.D., Ph.D. to its board of directors

DUBLIN, Nov. 19, 2021 – Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Cato T. Laurencin, M.D., Ph.D., to the company’s Board of Directors. Dr. Laurencin is a distinguished university professor, award-winning engineer, orthopaedic surgeon, scientist, administrator, and pioneer in the field of regenerative engineering. Dr. Laurencin is actively involved in mentoring and social justice initiatives and has been widely recognized for his work promoting diversity and excellence in science and addressing health disparities. He currently serves as a professor of multiple disciplines at the University of Connecticut (UConn). He is the University Professor and Van Dusen Distinguished Endowed Professor of Orthopaedic Surgery, Professor of Chemical and Biomolecular Engineering, Professor of Materials Science and Engineering and Professor of Biomedical Engineering. He is the Chief Executive Officer of The Connecticut Convergence Institute for Translation in Regenerative Engineering at UConn.

“Dr. Laurencin brings to the Alkermes Board significant experience across a wide range of medical and scientific disciplines, a focus on public health that is consistent with the company’s core values and business strategy, strong administrative skills, and a keen understanding of how scientific innovation has the potential to drive shareholder value creation,” said Richard Pops, Chief Executive Officer and Chairman of Alkermes. “In addition to his many scientific and administrative accomplishments, Dr. Laurencin is dedicated to important social justice research and initiatives, including raising awareness of, and addressing, racial and ethnic health disparities. We are delighted to welcome Dr. Laurencin as our sixth new independent director since 2019.”

“Throughout my career I have been motivated to advance medicine, engineering, science and social justice initiatives, along with direct administrative action, that have the potential to make a meaningful difference in people’s lives. I am pleased to join Alkermes’ Board of Directors and look forward to contributing to the company’s mission of advancing great science and deep compassion to develop innovative medicines that address real unmet patient needs,” said Dr. Laurencin.